Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls

Clinical and Translational Oncology

Volumn 14, Issue 5, 2012, Pages 356-361

  Oven Ustaalioglu, Basak ^a,c   Bilici, Ahmet ^a   Ercan, Serif ^a   Orcun, Asuman ^a   Seker, Mesut ^a   Ozkan, Alper ^a   Ustaalioglu, Recep ^b   Gumus, Mahmut ^a  

^a DR LUTFI KIRDAR KARTAL EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b Siyami Ersek Thoracic and Cardiovascular Surgery Hospital   (Turkey)

^c Selimiye Mah   (Turkey)

Author keywords

Advanced stage; Cut off; M30; M65; Non small cell lung cancer; Progression free survival

Indexed keywords

CYTOKERATIN 18; ONCOPROTEIN; PROTEIN M30; PROTEIN M65; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATIN-18; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84860704762     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0808-0     Document Type: Article

References (22)

1. Yaman E, Coskun U, Sancak B et al (2010) Serum M30 levels are associated with survival in advanced gastric carcinoma patients. Int Immunopharmacol 10:719-722
2. Dive C, Smith RA, Garner E et al (2010) Considerations for the use of plasma cytokeratin 18 as a biomarker in pancreatic cancer. Br J Cancer 102: 577-582
3. Sheard MA, Vojtesek B, Simickova M, Valik D (2002) Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis. J Cell Biochem 85: 670-677 (Pubitemid 34462778)
4. Kramer G, Erdal H, Mertens HJ et al (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751-1756 (Pubitemid 38428698)
5. Ueno T, Toi M, Linder S (2005) Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 59:359-362
6. Cummings J, Ranson M, Butt F et al (2007) Qualifi cation of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol 60:921-924 (Pubitemid 47389396)
7. Ulukaya E, Yilmaztepe A, Akgoz S et al (2007) The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival. Lung Cancer 56:399-404 (Pubitemid 46679086)
8. Olofsson MH, Ueno T, Pan Y et al (2007) Cytokeratin- 18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin Cancer Res 13:3198-3206 (Pubitemid 46944902)
9. Ausch C, Buxhofer-Ausch V, Olszewski U et al (2009) Caspase-cleaved cytokeratin 18 fragment (M30) as marker of postoperative residual tumor load in colon cancer patients. Eur J Surg Oncol 35:1164-1168
10. Ozturk B, Coskun U, Sancak B et al (2009) Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors. Int Immunopharmacol 9:645-648
11. Ueno T, Toi M, Bivén K et al (2003) Measurement of an apoptotic product in the sera of breast cancer patients. Eur J Cancer 39:769-774 (Pubitemid 36315993)
12. de Haas EC, di Pietro A, Simpson KL et al (2008) Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drugsensitive tumor, testicular cancer. Neoplasia 10: 1041-1048
13. Ginsberg MS, Grewal RK, Heelan RT (2007) Lung cancer. Radiol Clin North Am 45:21-43 (Pubitemid 44854042)
14. Jemal A, Siegel R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249
15. Goldstraw P, Crowley J, Chansky K et al; International Association for the Study of Lung Cancer International Staging Committee; Participating Institutions (2007) The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classifi cation of malignant tumours. J Thorac Oncol 2:706-714. (Pubitemid 47357522)
16. Erratum in: J Thorac Oncol 2007;2:985
17. Wu YX, Wang JH, Wang H, Yang XY (2003) [Study on expression of Ki-67, early apoptotic protein M30 in endometrial carcinoma and their correlation with prognosis] [Article in Chinese]. Zhonghua Bing Li Xue Za Zhi 32:314-318
18. Hou JM, Greystoke A, Lancashire L et al (2009) Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 175:808-816
19. Ausch C, Buxhofer-Ausch V, Olszewski U et al (2009) Circulating cytokeratin 18 fragment m65-a potential marker of malignancy in colorectal cancer patients. J Gastrointest Surg 13:2020-3026
20. Koelink PJ, Lamers CB, Hommes DW, Verspaget HW (2009) Circulating cell death products predict clinical outcome of colorectal cancer patients. BMC Cancer 9:88
21. Erler JT, Cawthorne CJ, Williams KJ et al (2004) Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24: 2875-2889 (Pubitemid 38381277)
22. Greystoke A, Cummings J, Ward T et al (2008) Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19:990-995 (Pubitemid 351627319)